Login
Navigate Fool.com
Will CORT beat
the market?
Community Rating: 2 Stars: Unattractive

3.83 0.21 (5.80%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.62
Previous Close $3.62
Daily Range $3.55 - $3.87
52-Week Range $1.47 - $4.49
Market Cap $385.2M
P/E Ratio -8.33
Dividend (Yield) $0.00 (0.0%)
Volume 421,704
Average Daily Volume 623,321
Current FY EPS -$0.33

How do you think CORT
will perform against the market?

Top CORT Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted September 23, 2011

For once I seem to have gotten lucky with a red thumb. I predicted incorrectly that the phase III study of Corlux in Cushing's disease would be a failure, given the prior failure of the drug for sever … More

0 Replies Reply Report this Post
 

zzlangerhans (< 20)
Submitted December 22, 2009

Corcept continues to flog Corlux, its pipeline in a teacup. The stock continues to get diluted as the phase III study of Corlux in Cushing's syndrome approaches a topline data release in mid-2010. As … More

1 Replies Reply Report this Post

News & Commentary

Why Corcept Therapeutics Incorporated Shares Dipped

Corcept shares drop after the company reports its fourth-quarter results. Is this a buying opportunity or a reason to hit the exits?

3 Biggest Laggards in Health Care Last Week

What droves shares of these three stocks down last week?

3 Horrendous Health-Care Stocks This Week

Why Intercept Pharmaceuticals, USANA Health Sciences, and Corcept Therapeutics were stinkers and sinkers this week.

3 Humongous Health-Care Stocks This Week

From great clinical results to a big buyout, Enanta, Given Imaging, and Corcept Therapeutics had humongous weeks.

Why Corcept Therapeutics Incorporated Shares Roared Higher

Corcept shares soar after the company announces the undertaking of a new research indication, as well as the filing of its first investigational new drug in this arena.

Assessing Raptor Pharmaceutical's Agreement With HealthCare Royalty Partners

January Top 10: Corcept

A look back at January's most incredible health-care stocks.

Three Biotech Movers to Watch in 2013

The Worst of 2012: Corcept Therapeutics

Nearing the end of our list of the very worst healthcare stocks of 2012, at No. 5 is Corcept Therapeutics, which came into 2012 like a lion and is going out like a lamb.

This Week in Biotech: Part 1

A look at the biggest stories in biotech this week and what they mean for investors.

See More CORT News...

Sector

Healthcare

Industry

Drugs

Corcept Therapeutics, Inc. (CORT) Description

A pharmaceutical company which is engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases. Website: http://www.corcept.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks